Glucose metabolism as a target of histone deacetylase inhibitors.
about
Energy metabolism in H460 lung cancer cells: effects of histone deacetylase inhibitorsRomidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approachesHistone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers.Critical role for lactate dehydrogenase A in aerobic glycolysis that sustains pulmonary microvascular endothelial cell proliferationMetabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.Trichostatin A modulates thiazolidinedione-mediated suppression of tumor necrosis factor α-induced lipolysis in 3T3-L1 adipocytesMutagenesis Study Reveals the Rim of Catalytic Entry Site of HDAC4 and -5 as the Major Binding Surface of SMRT CorepressorRedox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.Blastomere removal from cleavage-stage mouse embryos alters placental function, which is associated with placental oxidative stress and inflammation.Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells.Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor.GLUT1 as a therapeutic target in hepatocellular carcinoma.Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis.HDACi: cellular effects, opportunities for restorative dentistry.Predicting treatment outcome in classical Hodgkin lymphoma: genomic advancesClinical development of panobinostat in classical Hodgkin's lymphoma.Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions.Epigenetic regulation of glucose transporters in non-small cell lung cancer.Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice.[Advances in the research of glycolysis and lung cancer].Effects of Valproic Acid on Cerebral Nutrient Carriers' Expression in the RatMetabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
P2860
Q28479066-CEAB6855-84CC-4614-A034-1589B1604390Q33390876-C267A1EE-6044-4EAB-87A5-398945F20227Q33705588-9237CC61-8B6B-4037-8AD6-AC075BD3A05FQ33829390-15BB037D-CA2C-4158-80E3-62539383B95BQ33835913-416EFDEE-5543-4FEE-8078-BB92CB2ABBCBQ34109688-46814324-8E7E-40C9-8A70-0663446CAAC5Q34212709-5B5ABBF6-2388-474A-9EBD-0063A98F8A99Q34318242-DE5A6D3D-4ED9-472A-A27B-F19C07DFCCF0Q34645445-1AA51591-08B0-4345-AE5B-3112C2DD1647Q34949771-1B261468-3F98-44F4-89FA-59CE4E1A4341Q35687733-8341F8ED-1F1C-4A9E-8426-B43220F75AF4Q35822102-763DAA72-8034-448F-B6A8-8B8A4764F10BQ35953399-E4586467-3C48-4909-A105-51E2143CBB87Q36010195-34BE1FB1-FEEC-444B-8DB6-BFF2DC5E1E21Q36830264-1E72C275-710F-42E4-B9D6-D40D2058E372Q37119662-DAC3CE57-E5D2-4C81-9684-D6D2889A34B2Q37423469-B1459F7A-905E-41CE-94B1-D68651515FFEQ37623840-E75A6779-CC9C-48E5-9623-BAB6A77A282CQ37725533-B3BC9571-A22B-437C-B389-1116FD4D775EQ37871246-802F45F8-556F-4395-BA47-DADC6CF25EB6Q37872044-375251D5-A1AF-4B81-9C3B-0A85E4454527Q37888710-4E158A25-E634-4223-91A3-3DF9165C7F6EQ38753641-05A1052F-6331-4C14-A729-F60FC0588102Q42576918-BD397011-00B8-489E-8CDD-8107398EA7FFQ50067303-84778456-BAD4-4DFB-AD32-59BB91CF38DAQ55464273-FF8EA4E4-43D2-4F01-8C6F-46B45487883AQ57300057-AC0412C5-1908-4074-B50E-070492D8091AQ57816641-1B111786-3D50-451E-A68B-F889BEC03027
P2860
Glucose metabolism as a target of histone deacetylase inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glucose metabolism as a target of histone deacetylase inhibitors.
@en
Glucose metabolism as a target of histone deacetylase inhibitors.
@nl
type
label
Glucose metabolism as a target of histone deacetylase inhibitors.
@en
Glucose metabolism as a target of histone deacetylase inhibitors.
@nl
prefLabel
Glucose metabolism as a target of histone deacetylase inhibitors.
@en
Glucose metabolism as a target of histone deacetylase inhibitors.
@nl
P2093
P2860
P356
P1476
Glucose metabolism as a target of histone deacetylase inhibitors
@en
P2093
Christopher B Newgard
Donald P McDonnell
Heather L Wieman
Jeffrey C Rathmell
Olga R Ilkayeva
Suzanne E Wardell
P2860
P304
P356
10.1210/ME.2008-0179
P577
2008-12-23T00:00:00Z